Cardiovascular
A proposed settlement would resolve claims that Actelion used REMS restrictions to block generic rivals from accessing Tracleer samples, allegedly delaying competition and inflating prices for insurers and other payors.
The company blamed high placebo responses in Latin America and noted greater efficacy in sicker pulmonary arterial hypertension patients that make its kinase inhibitor worthy of FDA filing.
Deal Snapshot: Eli Lilly is the latest big pharma player to explore the potential of interleukin-6 in an multi-million dollar agreement with troubled Australian firm CSL.
Boehringer Ingelheim president of US human pharma Brian Hilberdink said he loves to launch and with up to 20 new product launches planned over the next five years, his team should be busy.
Boehringer Ingelheim is restructuring its therapeutic operations to push decision-making closer to brand teams while keeping R&D spending around 25% of revenues.
The impact of rising demand, Medicare price negotiations under the IRA, Medicaid concessions under its Trump administration drug pricing deal and direct-to-patient sales will combine to boost Eliquis sales this year.
Cardiovascular disease is moving to the top of the EU’s health agenda with the release of the Safe Hearts Plan, European Parliament scrutiny of which is expected at the end of Q1. Medical device companies applaud the initiative but will seek more input as the plan evolves.
Cardiovascular disease is moving to the top of the EU’s health agenda with the release of the Safe Hearts Plan, European Parliament scrutiny of which is expected at the end of Q1. Medical device companies applaud the initiative but will seek more input as the plan evolves.
ACC/AHA guidelines are reshaping US payer policies, expanding coverage and access to breakthrough cardiovascular therapies like SGLT2 and PCSK9 inhibitors. But costs, red tape, and uneven access still stand in the way.
Propelled by Abiomed and Shockwave Medical, global second-leading medtech group reports innovation-driven 6% revenue rise in 2025 and readies for deeper move into higher-growth markets ahead of anticipated US Ottava launch and separation of DePuy Synthes orthopedics.
The $172m acquisition will bring in Kylo-11, a Lp(a) inhibitor with potential once-yearly dosing, as well as other ultra long-acting siRNA candidates directed at APOC3, PCSK9 and other undisclosed targets in cardiovascular diseases.
The CEO of Inno Medicine tells Scrip the Chinese company has developed a novel active-targeting nano-liposomal formulation to reverse coronary atherosclerosis plaque, which has yielded positive proof-of-concept Phase Ib/IIa results.